Effect of Lipo-PGE1 on health-related quality of life in patients with systemic sclerosis and systemic lupus erythematosus in Japan.
作者： K Hoshi , S Fukuhara
DOI: 10.1177/147323000803600124
关键词:
摘要: We investigated the effect of Lipo-PGE(1), a prostaglandin (PG) E(1) preparation used to treat cutaneous ulcers associated with systemic sclerosis (SS) and lupus erythematosus (SLE), on health-related quality life (HR-QOL) using Medical Outcome Study 36-item Short-Form Health Survey (SF-36) questionnaire. A total 192 SS SLE patients were treated for 3 months. At baseline scores each five SF-36 subscales significantly lower than age- sex-adjusted standard values Japanese general population. After treatment, mean (+/- SD) body pain health perception increased from 48.6 +/- 24.1 55.3 26.1 36.8 16.7 40.2 17, respectively. Emotional QOL parameters including vitality mental health, however, showed no improvement. Physician-rated symptom improved after administration Lipo-PGE(1). In conclusion, Lipo-PGE(1) both HR-QOL, especially physical QOL.
sagepub.com
paperity.org参考文章(12)
Fukuhara S, Esato K, The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. International Angiology. ,vol. 23, pp. 238- 245 ,(2004)
Mizushima Y, Lipid microspheres as novel drug carriers. Drugs Under Experimental and Clinical Research. ,vol. 11, pp. 595- 600 ,(1985)
Anita Stewart, John Ware, Measuring Functioning and Well-Being: The Medical Outcomes Study Approach Duke University Press. ,(1992) , 10.7249/CB361
John E. Ware, Anita Stewart, Measuring Functioning and Well-Being Duke University Press. ,(1992)
A Mchomey Colleen, John E Ware Jr, ER Anastasia, The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care. ,vol. 31, pp. 247- 263 ,(1993) , 10.1097/00005650-199303000-00006
Colleen A. McHorney, John E. Ware, J F Rachel Lu, Cathy Donald Sherbourne, The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups Medical Care. ,vol. 32, pp. 40- 66 ,(1994) , 10.1097/00005650-199401000-00004
John E. Ware, Cathy Donald Sherbourne, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. ,vol. 30, pp. 473- 483 ,(1992) , 10.1097/00005650-199206000-00002
Shunichi Fukuhara, John E. Ware, Mark Kosinski, Sayuri Wada, Barbara Gandek, Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey Journal of Clinical Epidemiology. ,vol. 51, pp. 1045- 1053 ,(1998) , 10.1016/S0895-4356(98)00096-1
K. Hoshi, Approved indications of lipo-PGE1 in Japan Advanced Drug Delivery Reviews. ,vol. 20, pp. 171- 176 ,(1996) , 10.1016/0169-409X(95)00120-V
Y. Mizushima, A. Yanagawa, K. Hoshi, Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man Journal of Pharmacy and Pharmacology. ,vol. 35, pp. 666- 667 ,(2011) , 10.1111/J.2042-7158.1983.TB02862.X